Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


It's Not All About IO: Seven Drugs To Watch At ASCO

Executive Summary

Biomedtracker's review of ASCO abstracts revealed several drugs to watch outside of the immuno-oncology space at the annual cancer conference in Chicago, including market-expanding data for Roche's Perjeta and J&J's Zytiga, and Phase III data for AstraZeneca's PARP inhibitor Lynparza in breast cancer.


Related Content

Recent And Upcoming FDA Advisory Committee Meetings
Incyte Eyes Big Phase III IDO Expansion, NewLink Plans First Pivotal Trial
Xtandi Sales Disappoint Pfizer, Returning Focus To The High-Priced Deal
Veliparib Phase III Failures Strike Blow To AbbVie's Oncology Strategy
Rebates, Pricing Pressure Weigh On J&J's Q1 Pharma Sales
Pipeline Watch: Phase III Readouts For Alectinib and Omadacycline
IDO Emerges As Clean Combo Partner, Rising Star At AACR
Puma's Neratinib SUMMIT Study Shows Potential & Pitfalls Of Precision Medicine
Roche Relief As APHINITY Trial Boosts Outlook On Its Oncology Business
Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts